Advanced searches left 3/3

Carboplatin Non-small Cell - Europe PMC

Summarized by Plex Scholar
Last Updated: 25 August 2022

* If you want to update the article please login/register

Atezolizumab plus carboplatin and nab-paclitaxel versus carboplatin and nab-paclitaxel as treatments for Chinese, treatment-naïve, stage IV, non-squamous, non-small-cell lung cancer patients: A retrospective analysis.

In treatment-nau00efve Chinese patients with suspected stage IV, non-squamous, non-small-cell lung cancer, we investigated the effectiveness and safety profile of atezolizumab plus carboplatin and nab-paclitaxel in treatment-nab-paclitaxel, non-squamous, non-small-cell lung cancer patients. More than 1200 mg/ml/min area - under the curve at least, three weeks or 6 mg/min area - under the age of cure carboplatin/ml/min, nab-paclitaxel/ml/min area, under-the-curve carboplatin/3 weeks plus 60 mg/ml/min; week under international standards without exception (nab-pactaxel/week) • paclitaxel/ml/min Patients in the ACN cohort's first 48 weeks of follow-up were healthier than those in the CNP cohort, with progression-free survival and overall survival in the ACN cohort. ACN cohort and 94 in the CNP cohort all received a grade u22653 adverse events, with a total of 97 patients. During 48 weeks of follow-up, 84 patients from the ACN cohort and 107 from the CNP cohort died.

Source link: https://europepmc.org/article/MED/35568997

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions